See more : Xchanging Solutions Limited (XCHANGING.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Eliem Therapeutics, Inc. (ELYM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eliem Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aurora Spine Corporation (ASG.V) Income Statement Analysis – Financial Results
- Country Garden Services Holdings Company Limited (CTRGF) Income Statement Analysis – Financial Results
- Nilörngruppen AB (NIL-B.ST) Income Statement Analysis – Financial Results
- Northway Financial, Inc. (NWYF) Income Statement Analysis – Financial Results
- Shibaura Mechatronics Corporation (6590.T) Income Statement Analysis – Financial Results
Eliem Therapeutics, Inc. (ELYM)
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 15.41M | 26.21M | 23.32M | 9.34M | 4.02M |
| General & Administrative | 9.89M | 18.92M | 12.35M | 2.43M | 677.00K |
| Selling & Marketing | 24.85M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.89M | 18.92M | 12.35M | 2.43M | 677.00K |
| Other Expenses | 0.00 | 1.38M | -11.64M | 0.00 | 914.00K |
| Operating Expenses | 37.41M | 45.14M | 35.67M | 11.77M | 4.70M |
| Cost & Expenses | 37.41M | 45.14M | 35.67M | 11.77M | 4.70M |
| Interest Income | 0.00 | 1.20K | 450.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.59M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.47M | 45.14M | 35.67M | 11.77M | 4.70M |
| EBITDA | -13.65M | -43.65M | -35.50M | -2.87M | -1.93M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.47M | -45.14M | -35.67M | -20.93M | -7.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.65M | -109.00K | -11.81M | 257.00K | 899.00K |
| Income Before Tax | -35.12M | -45.24M | -47.48M | -20.67M | -6.55M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -21.47K | 109.00K | -66.56K | -9.16M | -2.75M |
| Net Income | -35.12M | -45.35M | -47.48M | -11.51M | -3.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| EPS Diluted | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| Weighted Avg Shares Out | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
| Weighted Avg Shares Out (Dil) | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting
Eliem Therapeutics to Present at Stifel's 2022 CNS Days
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Eliem Therapeutics Reports Second Quarter Financial Results
U.S. IPO Weekly Recap: Summer's Last Wave With 2 IPOs
Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Eliem Therapeutics Announces Pricing of Initial Public Offering
Eliem Therapeutics Aims For $81 Million U.S. IPO
Source: https://incomestatements.info
Category: Stock Reports